Canada markets close in 1 hour 31 minutes

Nordicus Partners Corporation (NORD)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
0.50000.0000 (0.00%)
As of 11:31AM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Previous Close0.5000
Open0.6500
BidN/A x N/A
AskN/A x N/A
Day's Range0.5000 - 0.5000
52 Week Range0.4500 - 0.9200
Volume319
Avg. Volume236
Market Cap5.516M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-0.2500
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • GlobeNewswire

    Nordicus Partners Corporation Acquires 95% Stake in Orocidin A/S

    Beverly Hills, California., May 15, 2024 (GLOBE NEWSWIRE) -- Nordicus Partners Corporation (OTCQB: NORD) (“Nordicus” or the “Company”), a financial consulting company specializing in providing Nordic and U.S. Life Sciences companies with optimal conditions to establish themselves on the U.S. market, announced today that it has entered into an agreement with Orocidin A/S (“Orocidin”) to acquire a 95% stake from eleven of Orocidin’s shareholders for $38,000,000. Nordicus will be issuing 38 million

  • GlobeNewswire

    Nordicus Partners Corporation Uplists to OTCQB

    Beverly Hills, California., May 09, 2024 (GLOBE NEWSWIRE) -- Nordicus Partners Corporation (OTCQB: NORD) (“Nordicus” or the “Company”), a financial consulting company specializing in providing Nordic and U.S. Life Sciences companies with optimal conditions to establish themselves on the U.S. market, today announced that it has uplisted to the OTCQB. OTCQB is recognized by the SEC as an established public securities market. OTCQB companies must provide current company financial information/news a

  • GlobeNewswire

    NORDICUS PARTNERS CORPORATION ENTERS INTO A CONSULTANCY AGREEMENT WITH OROCIDIN A/S IN DENMARK

    Beverly Hills, California., Jan. 10, 2024 (GLOBE NEWSWIRE) -- Nordicus Partners Corporation (OTC PINK: NORD) (“Nordicus” or the “Company”), a financial consulting company specializing in providing Nordic and U.S. Life Sciences companies with optimal conditions to establish themselves on the U.S. market, today announced it entered into a paying Consultancy Agreement with Orocidin A/S in Denmark. Orocidin A/S (“Orocidin”) is a clinical-stage biopharmaceutical company focused on the discovery, deve